Oncolix - Dedicated to the discovery and development of novel biotherapeutics

 

PUBLICATIONS

Chen, WY, Wight, DC, Wagner, TE and Kopchick, JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc. Natl. Acad. Sci., USA, 87, 5061-5065, 1990.

Chen, WY, Wight, DC, Chen, NY, Wagner, TE, and Kopchick, JJ. Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice. J. Biol. Chem., 266, 2252-2258, 1991.

Chen, WY, White, ME, Wagner, TE and Kopchick, JJ. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in transgenic dwarf mice. Endocrinology, 129, 1402-1408, 1991.

Chen, WY, Wight, DC, Mehta, BV, Wagner, TE and Kopchick, JJ. Glycine 119 of bovine growth hormone is critical for growth promoting activity. Mol. Endocrinology, 5, 1845-1852, 1991.

Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 5, 3583-93, 1999.

Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Internatl J Oncol, 20:813-818, 2002.

Beck MT, Peirce SK and Chen WY. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21, 5047-55, 2002.

Zhang GR, Li W, Holle H, Chen NY and Chen WY. A novel design of targeted endocrine and cytokine therapy for human breast cancer. Clin. Cancer Res., 8:1196-1205, 2002.

Beck MT, Chen, NY, Franek K and Chen WY. Prolactin Antagonist Endostatin Fusion Protein as A Targeted Dual Functional Therapeutic Agent for Breast Cancer. Cancer Res., 63:3598-3604, 2003.

Peirce S and Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 23:1248–1255, 2004.

Langenheim JF. and Chen WY. Development of a Prolactin Receptor-Targeting Fusion Toxin Using a Prolactin Antagonist and a Recombinant Form of Pseudomonas Exotoxin A. Breast Cancer Res. and Treatment. 90:281-93, 2005.

Langenheim JF. Tan D, Walker AM and Chen WY. Two wrongs can make a right: dimers of human prolactin and growth hormone antagonists behave as agonists. Mol Endocrinol. 20(3):661-74, 2006.

Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and Herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 111(2):241-50, 2007.

Home :: About Us :: Our Science :: Strategic Alliances :: News & Publications :: Careers :: Contact Us

©2010 Oncolix, Inc. All Rights Reserved.

Oncolix